CRISPR in cancer biology and therapy

A Katti, BJ Diaz, CM Caragine, NE Sanjana… - Nature Reviews …, 2022 - nature.com
Over the past decade, CRISPR has become as much a verb as it is an acronym,
transforming biomedical research and providing entirely new approaches for dissecting all …

Multiplexed CRISPR technologies for gene editing and transcriptional regulation

NS McCarty, AE Graham, L Studená… - Nature …, 2020 - nature.com
Multiplexed CRISPR technologies, in which numerous gRNAs or Cas enzymes are
expressed at once, have facilitated powerful biological engineering applications, vastly …

Small RNAs are modified with N-glycans and displayed on the surface of living cells

RA Flynn, K Pedram, SA Malaker, PJ Batista… - Cell, 2021 - cell.com
Glycans modify lipids and proteins to mediate inter-and intramolecular interactions across all
domains of life. RNA is not thought to be a major target of glycosylation. Here, we challenge …

IL-1β+ macrophages fuel pathogenic inflammation in pancreatic cancer

N Caronni, F La Terza, FM Vittoria, G Barbiera… - Nature, 2023 - nature.com
Pancreatic ductal adenocarcinoma (PDAC) is a lethal disease with high resistance to
therapies. Inflammatory and immunomodulatory signals co-exist in the pancreatic tumour …

[HTML][HTML] Quantitative high-confidence human mitochondrial proteome and its dynamics in cellular context

M Morgenstern, CD Peikert, P Lübbert, I Suppanz… - Cell metabolism, 2021 - cell.com
Mitochondria are key organelles for cellular energetics, metabolism, signaling, and quality
control and have been linked to various diseases. Different views exist on the composition of …

Human genetic diversity alters off-target outcomes of therapeutic gene editing

S Cancellieri, J Zeng, LY Lin, M Tognon, MA Nguyen… - Nature …, 2023 - nature.com
CRISPR gene editing holds great promise to modify DNA sequences in somatic cells to treat
disease. However, standard computational and biochemical methods to predict off-target …

Inhibition of PCSK9 potentiates immune checkpoint therapy for cancer

X Liu, X Bao, M Hu, H Chang, M Jiao, J Cheng, L Xie… - Nature, 2020 - nature.com
Despite its success in achieving the long-term survival of 10–30% of treated individuals,
immune therapy is still ineffective for most patients with cancer,. Many efforts are therefore …

IKKβ primes inflammasome formation by recruiting NLRP3 to the trans-Golgi network

NA Schmacke, F O'Duill, MM Gaidt, I Szymanska… - Immunity, 2022 - cell.com
The NLRP3 inflammasome plays a central role in antimicrobial defense as well as in the
context of sterile inflammatory conditions. NLRP3 activity is governed by two independent …

[HTML][HTML] The glucose transporter GLUT3 controls T helper 17 cell responses through glycolytic-epigenetic reprogramming

SM Hochrein, H Wu, M Eckstein, L Arrigoni, JS Herman… - Cell metabolism, 2022 - cell.com
Metabolic reprogramming is a hallmark of activated T cells. The switch from oxidative
phosphorylation to aerobic glycolysis provides energy and intermediary metabolites for the …

[HTML][HTML] Strategies to overcome the main challenges of the use of CRISPR/Cas9 as a replacement for cancer therapy

MF Rasul, BM Hussen, A Salihi, BS Ismael, PJ Jalal… - Molecular Cancer, 2022 - Springer
CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats-associated protein
9) shows the opportunity to treat a diverse array of untreated various genetic and …